172 related articles for article (PubMed ID: 24656614)
1. Nano-antibiotics in chronic lung infection therapy against Pseudomonas aeruginosa.
Hadinoto K; Cheow WS
Colloids Surf B Biointerfaces; 2014 Apr; 116():772-85. PubMed ID: 24656614
[TBL] [Abstract][Full Text] [Related]
2. Antimicrobial efficacy of tobramycin polymeric nanoparticles for Pseudomonas aeruginosa infections in cystic fibrosis: formulation, characterisation and functionalisation with dornase alfa (DNase).
Deacon J; Abdelghany SM; Quinn DJ; Schmid D; Megaw J; Donnelly RF; Jones DS; Kissenpfennig A; Elborn JS; Gilmore BF; Taggart CC; Scott CJ
J Control Release; 2015 Jan; 198():55-61. PubMed ID: 25481442
[TBL] [Abstract][Full Text] [Related]
3. Antibiotic-free nanotherapeutics: ultra-small, mucus-penetrating solid lipid nanoparticles enhance the pulmonary delivery and anti-virulence efficacy of novel quorum sensing inhibitors.
Nafee N; Husari A; Maurer CK; Lu C; de Rossi C; Steinbach A; Hartmann RW; Lehr CM; Schneider M
J Control Release; 2014 Oct; 192():131-40. PubMed ID: 24997276
[TBL] [Abstract][Full Text] [Related]
4. Tailored Nanocarriers for the Pulmonary Delivery of Levofloxacin against Pseudomonas aeruginosa: A Comparative Study.
Derbali RM; Aoun V; Moussa G; Frei G; Tehrani SF; Del'Orto JC; Hildgen P; Roullin VG; Chain JL
Mol Pharm; 2019 May; 16(5):1906-1916. PubMed ID: 30900903
[TBL] [Abstract][Full Text] [Related]
5. Green preparation of antibiotic nanoparticle complex as potential anti-biofilm therapeutics via self-assembly amphiphile-polyelectrolyte complexation with dextran sulfate.
Cheow WS; Hadinoto K
Colloids Surf B Biointerfaces; 2012 Apr; 92():55-63. PubMed ID: 22154010
[TBL] [Abstract][Full Text] [Related]
6. Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections.
Meers P; Neville M; Malinin V; Scotto AW; Sardaryan G; Kurumunda R; Mackinson C; James G; Fisher S; Perkins WR
J Antimicrob Chemother; 2008 Apr; 61(4):859-68. PubMed ID: 18305202
[TBL] [Abstract][Full Text] [Related]
7. Challenges with current inhaled treatments for chronic Pseudomonas aeruginosa infection in patients with cystic fibrosis.
Greally P; Whitaker P; Peckham D
Curr Med Res Opin; 2012 Jun; 28(6):1059-67. PubMed ID: 22401602
[TBL] [Abstract][Full Text] [Related]
8. Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas aeruginosa.
Alipour M; Suntres ZE
Ther Deliv; 2014 Apr; 5(4):409-27. PubMed ID: 24856168
[TBL] [Abstract][Full Text] [Related]
9. Pseudomonas aeruginosa chromosomal beta-lactamase in patients with cystic fibrosis and chronic lung infection. Mechanism of antibiotic resistance and target of the humoral immune response.
Ciofu O
APMIS Suppl; 2003; (116):1-47. PubMed ID: 14692154
[TBL] [Abstract][Full Text] [Related]
10. Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin.
Ehsan Z; Clancy JP
Future Microbiol; 2015; 10(12):1901-12. PubMed ID: 26573178
[TBL] [Abstract][Full Text] [Related]
11. Inhaled ciprofloxacin for chronic airways infections caused by Pseudomonas aeruginosa.
Antonela Antoniu S
Expert Rev Anti Infect Ther; 2012 Dec; 10(12):1439-46. PubMed ID: 23253321
[TBL] [Abstract][Full Text] [Related]
12. Antibacterial activity of liposomal gentamicin against Pseudomonas aeruginosa: a time-kill study.
Rukholm G; Mugabe C; Azghani AO; Omri A
Int J Antimicrob Agents; 2006 Mar; 27(3):247-52. PubMed ID: 16472992
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of inhaled antibiotic liposome versus antibiotic nanoplex in controlling infection in bronchiectasis.
Tran TT; Yu H; Vidaillac C; Lim AYH; Abisheganaden JA; Chotirmall SH; Hadinoto K
Int J Pharm; 2019 Mar; 559():382-392. PubMed ID: 30731256
[TBL] [Abstract][Full Text] [Related]
14. Ultrasmall TPGS-PLGA Hybrid Nanoparticles for Site-Specific Delivery of Antibiotics into
Wan F; Bohr SS; Kłodzińska SN; Jumaa H; Huang Z; Nylander T; Thygesen MB; Sørensen KK; Jensen KJ; Sternberg C; Hatzakis N; Mørck Nielsen H
ACS Appl Mater Interfaces; 2020 Jan; 12(1):380-389. PubMed ID: 31804792
[TBL] [Abstract][Full Text] [Related]
15. MP-376 (Aeroquin) for chronic Pseudomonas aeruginosa infections.
Azoicai D; Antoniu SA
Expert Opin Investig Drugs; 2013 Feb; 22(2):267-76. PubMed ID: 23176385
[TBL] [Abstract][Full Text] [Related]
16. Antimicrobial properties of liposomal azithromycin for Pseudomonas infections in cystic fibrosis patients.
Solleti VS; Alhariri M; Halwani M; Omri A
J Antimicrob Chemother; 2015 Mar; 70(3):784-96. PubMed ID: 25416744
[TBL] [Abstract][Full Text] [Related]
17. Associations between antibiotic use and changes in susceptibility patterns of Pseudomonas aeruginosa in a private, university-affiliated teaching hospital: an 8-year-experience: 1995-2002.
Mohr JF; Jones A; Ostrosky-Zeichner L; Wanger A; Tillotson G
Int J Antimicrob Agents; 2004 Oct; 24(4):346-51. PubMed ID: 15380259
[TBL] [Abstract][Full Text] [Related]
18. Optimization of anti-pseudomonal antibiotics for cystic fibrosis pulmonary exacerbations: VI. Executive summary.
Zobell JT; Young DC; Waters CD; Ampofo K; Stockmann C; Sherwin CM; Spigarelli MG
Pediatr Pulmonol; 2013 Jun; 48(6):525-37. PubMed ID: 23359557
[TBL] [Abstract][Full Text] [Related]
19. Co-encapsulation of gallium with gentamicin in liposomes enhances antimicrobial activity of gentamicin against Pseudomonas aeruginosa.
Halwani M; Yebio B; Suntres ZE; Alipour M; Azghani AO; Omri A
J Antimicrob Chemother; 2008 Dec; 62(6):1291-7. PubMed ID: 18931388
[TBL] [Abstract][Full Text] [Related]
20. Disassembling bacterial extracellular matrix with DNase-coated nanoparticles to enhance antibiotic delivery in biofilm infections.
Baelo A; Levato R; Julián E; Crespo A; Astola J; Gavaldà J; Engel E; Mateos-Timoneda MA; Torrents E
J Control Release; 2015 Jul; 209():150-8. PubMed ID: 25913364
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
